Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Long-term Activity Ratios (Summary)

Pfizer Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The investment activity ratios exhibit a synchronized pattern characterized by a significant decline throughout 2022 and 2023, reaching a nadir in the first quarter of 2024, followed by a period of relative stability and marginal recovery through June 2026.

Net Fixed Asset Turnover
A peak of 6.64 was recorded in July 2022, followed by a sustained downward trend that bottomed out at 2.97 in June 2024. Following this contraction, the ratio entered a stabilization phase, fluctuating within a narrow band between 3.24 and 3.46, and concluding the period at 3.35 in June 2026.
Total Asset Turnover
Efficiency in total asset utilization decreased from a high of 0.52 in July 2022 to a minimum of 0.25 by March 2024. A gradual recovery was observed from late 2024 onward, with the ratio stabilizing between 0.30 and 0.32 for the final six quarters of the analyzed period.
Equity Turnover
The ratio of revenue to equity mirrored the broader asset trends, declining from 1.16 in July 2022 to a low of 0.61 in March 2024. Subsequently, a moderate recovery occurred, with the ratio trending upward to end at 0.75 in June 2026.

The simultaneous decline across all turnover metrics between mid-2022 and early 2024 suggests a period of significant balance sheet expansion or a reduction in revenue generation relative to the investment base. The subsequent plateauing of these ratios indicates that the organization has reached a new operational equilibrium, where the utilization of fixed assets, total assets, and equity has stabilized at a lower efficiency level compared to the 2022 peak.



Net Fixed Asset Turnover

Pfizer Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Revenues
Property, plant and equipment, net of accumulated depreciation
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Net fixed asset turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Property, plant and equipment, net of accumulated depreciation
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of the net fixed asset turnover ratio reveals a significant contraction in asset productivity between the second quarter of 2022 and the first half of 2024, followed by a period of relative stabilization through mid-2026.

Revenue Trends
A substantial decline in quarterly revenues is observed, starting from a peak of 27,742 million US dollars in July 2022 and falling to a low of 13,007 million US dollars by July 2023. While a moderate recovery occurred throughout 2024 and 2025, with revenues fluctuating between 13,283 million and 17,763 million US dollars, they remained significantly below the levels recorded in early 2022.
Fixed Asset Investment
Property, plant, and equipment, net of accumulated depreciation, exhibited a consistent upward trend from April 2022 (15,109 million US dollars) through December 2023 (18,940 million US dollars). Following this period of expansion, the fixed asset base remained relatively stable, oscillating between 18,347 million and 19,402 million US dollars through June 2026.
Net Fixed Asset Turnover Interpretation
The net fixed asset turnover ratio experienced a sharp decline from a high of 6.64 in July 2022 to a trough of 2.97 in June 2023. This deterioration was driven by the simultaneous occurrence of falling revenues and an increasing investment in fixed assets, indicating a decrease in the efficiency of the company's long-term asset base in generating sales. From late 2023 through mid-2026, the ratio stabilized, fluctuating within a narrow range between 2.98 and 3.46, suggesting that the asset utilization rate reached a new equilibrium as revenue volatility subsided and capital expenditures leveled off.


Total Asset Turnover

Pfizer Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Revenues
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Total asset turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio exhibits a distinct three-phase trajectory characterized by initial stability, a sharp contraction, and a subsequent period of gradual stabilization. This trend reflects a significant shift in the efficiency with which assets are utilized to generate revenue.

Revenue and Asset Correlation
A period of high operational efficiency is observed in the first half of 2022, where revenues peaked at 27.7 billion USD against a total asset base of approximately 195 billion USD. However, a misalignment occurred throughout 2023, as revenues declined sharply to a low of 13.0 billion USD in July 2023, while total assets simultaneously increased, reaching a peak of 226.5 billion USD by December 2023. This inverse movement between revenue generation and asset accumulation drove the precipitous drop in the turnover ratio.
Analysis of the Asset Turnover Ratio
The turnover ratio remained consistently above 0.50 during early 2022, indicating a relatively efficient conversion of assets into sales. A severe deterioration followed, with the ratio falling to 0.26 by December 2023 and hitting a nadir of 0.25 in March 2024. This decline represents a substantial reduction in asset productivity.
Recovery and Stabilization Phase
From mid-2024 through mid-2026, a modest recovery is evident. The ratio climbed from 0.26 to a stabilized range between 0.30 and 0.32. This improvement is attributed to a combination of recovering quarterly revenues—reaching as high as 17.7 billion USD in late 2024—and a strategic reduction in the total asset base, which declined from its 2023 peak to approximately 201 billion USD by June 2026.


Equity Turnover

Pfizer Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Revenues
Total Pfizer Inc. shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Equity turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Total Pfizer Inc. shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of equity turnover reveals a significant shift in capital efficiency from early 2022 through mid-2026. An initial period of high asset utilization was followed by a sharp contraction, eventually transitioning into a period of stabilization at a lower baseline.

Revenue Trajectory
A notable volatility in top-line performance is observed. Revenues peaked in early 2022, reaching $27.7 billion in July 2022, before experiencing a substantial decline through 2023, where values dropped to as low as $13.0 billion. From 2024 through mid-2026, revenues exhibited a partial recovery and stabilization, generally fluctuating between $13.2 billion and $17.7 billion.
Shareholders' Equity Evolution
The equity base showed a consistent upward trend during the first year of the period, rising from $82.4 billion in April 2022 to a peak of $100.9 billion in April 2023. Following this peak, shareholders' equity entered a period of gradual contraction and fluctuation, settling into a range between $85.1 billion and $92.8 billion from 2024 onwards.
Equity Turnover Ratio Dynamics
The equity turnover ratio demonstrates a strong negative correlation with the expansion of the equity base and the contraction of revenues. The ratio declined from a high of 1.16 in July 2022 to a low of 0.61 by March 2024. This downturn indicates a reduction in the company's ability to generate sales relative to its equity investment during this window.
Stabilization and Recovery Patterns
Starting in the second quarter of 2024, the turnover ratio ceased its precipitous decline and began to stabilize. Between June 2024 and June 2026, the ratio fluctuated within a narrow band of 0.64 to 0.75. This suggests a realignment of the company's operational scale with its capital structure, resulting in a more consistent, albeit lower, level of equity efficiency compared to 2022 levels.